ARCHIVES

“Spoiled, Petulant Brat”: BioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

This article is from The Cancer Letter archive.

Vol. 39 No. 42 | November 8, 2013

Download PDF Visit The Full Archive

Related Articles

Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL

June 11, 2014

No Benefit To Shark Cartilage As Treatment, Large Trial Finds

July 27, 2007

FASEB Urges Better Funding, Management Of Biomedical Research

February 23, 1996

Preventive Oncology Announcement Withdrawn For Modification

April 3, 1981

In Brief: St. Jude, Yale to Get Bristol-Myers Grants; Five Named for New Young Scientists Awards

May 6, 1988

Sept. Is AMA’s Month of Women In Medicine

September 10, 1993